HAYWARD, Calif.--(BUSINESS WIRE)--RefleXion® Medical, an external-beam theranostic oncology company, today announced it will showcase Multi-target Treatment (MTT), the groundbreaking upgrade for its RefleXion® X1 platform. This innovation allows physicians to combine SCINTIX® biology-guided radiotherapy with conventional stereotactic body radiotherapy (SBRT) in a single plan to treat patients with metastatic disease.

加利福尼亚州海沃德（商业新闻短讯）--外部束治疗诊断肿瘤学公司RefleXion®Medical今天宣布将展示多靶点治疗（MTT），这是其RefleXion®X1平台的突破性升级。这项创新使医生能够将闪烁生物引导放射治疗与常规立体定向放射治疗（SBRT）结合在一起，以治疗转移性疾病患者。

The company will also highlight learnings from its early patient treatments..

该公司还将重点介绍早期患者治疗的经验教训。。

RefleXion will showcase MTT at the American Society for Radiation Oncology (ASTRO) Annual Meeting, Sept. 29 – Oct. 3, in Washington D.C. (booth #1313), where researchers will present new scientific evidence in 22 presentations, including four oral presentations, showcasing the X1 machine with SCINTIX therapy..

Reflection将于9月29日至10月3日在华盛顿举行的美国放射肿瘤学会（ASTRO）年会上展示MTT（展位#1313），研究人员将在22次演示中展示新的科学证据，包括四次口头演示，展示X1机器与闪烁治疗。。

“The results from our first-year patient treatments are highly encouraging,” said Sean Shirvani, M.D., M.P.H., chief medical officer at RefleXion. “We are consistently observing that SCINTIX therapy detects and adapts to tumor motion in an autonomous fashion. In the lung, this means that less normal lung tissue is damaged by the ablative zone of radiotherapy.

“我们第一年患者治疗的结果非常令人鼓舞，”RefleXion首席医疗官、医学博士SeanShirvani说。“我们一直观察到闪烁治疗以自主方式检测并适应肿瘤运动。在肺部，这意味着较少的正常肺组织受到放射治疗消融区的损害。

And in the bone, our system provides insurance against unanticipated shifts by the patient when the radiotherapy beam is on..

在骨骼中，我们的系统为放射治疗束打开时患者的意外转移提供了保险。。

“Moreover, our clinical partners recognize the immense value of having positron emission tomography or PET data underpinning both treatment planning and delivery. This information has, in several cases, influenced the course of patient therapy,” continued Shirvani.

“此外，我们的临床合作伙伴认识到正电子发射断层扫描或PET数据支持治疗计划和交付的巨大价值。在某些情况下，这些信息影响了患者的治疗过程，”Shirvani继续说道。

The RefleXion X1 with SCINTIX therapy uses information from an injected PET radiopharmaceutical produced by the cancer itself in real time to determine where to deliver radiation. Because PET data is used to direct treatment, it is also an integral part of the treatment planning process.

使用闪烁疗法的反射X1使用来自癌症本身实时产生的注射PET放射性药物的信息来确定在哪里传递辐射。由于PET数据用于指导治疗，因此它也是治疗计划过程的组成部分。

In early SCINTIX therapy cases, PET data during treatment planning or delivery demonstrated tumor progression, uncovered additional tumors, or confirmed significant tumor movement in bone tumors, which are generally considered relatively immobile. In the bone tumor cases, SCINTIX technology accurately followed the live PET signal and delivered the dose as planned, a feat not achievable with conventional image-guided radiotherapy..

在早期闪烁治疗病例中，治疗计划或分娩期间的PET数据显示肿瘤进展，发现其他肿瘤，或证实骨肿瘤中有明显的肿瘤运动，通常认为骨肿瘤相对不动。在骨肿瘤病例中，闪烁体技术准确地跟踪了活体PET信号并按计划提供了剂量，这是常规图像引导放射治疗无法实现的。。

The following oral presentations highlight some of the new research being presented at ASTRO 2024. Detailed information on all 22 presentations may be found here.

以下口头报告重点介绍了在ASTRO 2024上提出的一些新研究。有关所有22个演示文稿的详细信息，请参见此处。

Sunday, Sept. 29, 3:37 pm, room 147 – Scientific Development and Clinical Deployment of BgRT

9月29日星期日下午3:37，147室-BgRT的科学开发和临床部署

Monday, Sept. 30, 3:00 pm, room 145 – Early Clinical Insights into FDG-Guided Radiotherapy Planning and Delivery on a Novel PET-Linac Platform in Patients with Lung and Bone Lesions: Pioneering Real-Time Biology-guided Radiotherapy

9月30日，星期一，下午3:00，145室–在新型PET直线加速器平台上对肺部和骨骼病变患者进行FDG引导放疗计划和分娩的早期临床见解：开创性的实时生物学引导放疗

Monday, Sept. 30, 3:50 pm, room 145 – Feasibility of Biology-guided Radiotherapy with Gallium-68 PSMA-11 Radiotracer for Bony Metastases in Prostate Cancer Patients

9月30日星期一下午3:50，145室-用镓-68 PSMA-11放射性示踪剂进行生物引导放射治疗前列腺癌患者骨转移的可行性

Tuesday, Oct. 1, 8:40 am, room 152 – Impact of Synthetic PET Evaluation Prior to PET-Guided Functional Modeling in Optimizing Patient Selection for Biology-guided Radiotherapy

10月1日星期二上午8:40，152室–在PET引导的功能建模之前进行合成PET评估对优化生物引导放疗患者选择的影响

RefleXion’s booth will feature a multi-target SCINTIX technology interactive demonstration and SCINTIX treatment planning demonstrations.

RefleXion的展台将展示多目标闪烁技术交互式演示和闪烁治疗计划演示。

About RefleXion Medical

关于Reflection Medical

RefleXion is a privately held external-beam theranostic oncology company located in Hayward, Calif., commercializing SCINTIX biology-guided radiotherapy, a novel therapy that uses a single radiotracer injection to transform cancer cells into real-time biological beacons to control external-beam radiotherapy delivery to single or multiple tumors.

Reflection是一家位于加利福尼亚州海沃德的私营外部束治疗诊断肿瘤公司，将闪烁生物引导放射治疗商业化，这是一种使用单一放射性示踪剂注射将癌细胞转化为实时生物信标以控制外部束放射治疗传递至单个或多个肿瘤的新型疗法。

SCINTIX therapy is indicated for use in FDG-guided treatment of lung and bone tumors arising from either primary lung and bone cancers or resulting from metastases by other primary cancers that have each been assessed with onboard PET/CT prior to delivery to ensure adherence to X1 requirements for SCINTIX delivery.

闪烁治疗适用于FDG引导下治疗原发性肺癌和骨癌引起的肺和骨肿瘤，或由其他原发性癌症转移引起的肺和骨肿瘤，这些原发性癌症在分娩前均已通过车载PET/CT进行评估，以确保遵守闪烁交付的X1要求。

In addition to SCINTIX therapy, the RefleXion X1 is also FDA-cleared for conventional image-guided radiotherapy for solid tumors located anywhere in the body. For more information, please visit www.reflexion.com..

除了闪烁治疗外，Reflection X1还被FDA批准用于位于身体任何部位的实体瘤的常规图像引导放射治疗。有关更多信息，请访问www.reflexion.com。。